Seamus  Mulligan net worth and biography

Seamus Mulligan Biography and Net Worth

Seamus Mulligan brings a diverse industry background and global business acumen. His professional experience includes working in specialty pharmaceuticals, drug delivery systems and with the National Pharmaceutical Council. His pharmaceutical and biopharmaceutical experience ranges from the development stage to commercialization. Mr. Mulligan earned a Bachelor and Masters of Science but set his career sights on exploring the intersection of healthcare and business.

Mr. Mulligan has served as a member of our board of directors since January 2012 and was a founder and principal investor of Azur Pharma. From 2014 until 2018, Mr. Mulligan served as Chairman and Chief Executive Officer of Adapt Pharma Ltd., a specialty pharmaceutical company, which was acquired in October 2018 by Emergent BioSolutions Inc., a multinational specialty biopharmaceutical company, where Mr. Mulligan served on the board of directors until May 2020. From 2006 to April 2017, Mr. Mulligan served as Executive Chairman of Circ Pharma Limited and its subsidiaries, a pharmaceutical development stage group. Mr. Mulligan served as our Chief Business Officer, International Business Development from January 2012 until February 2013. Mr. Mulligan served as Azur Pharma’s Chairman and Chief Executive Officer and as a member of its board of directors from 2005 until January 2012. From 1984 until 2004, he held various positions with Elan Corporation, plc, a pharmaceutical company, most recently as Executive Vice President, Business and Corporate Development, and prior to that position, held the roles of President of Elan Pharmaceutical Technologies, the drug delivery division of Elan Corporation, plc, Executive Vice President, Pharmaceutical Operations, Vice President, U.S. Operations and Vice President, Product Development. He served as a member of the board of directors of the U.S. National Pharmaceutical Council until 2004. Mr. Mulligan received a B.Sc (Pharm) and M.Sc from Trinity College Dublin.

What is Seamus Mulligan's net worth?

The estimated net worth of Seamus Mulligan is at least $134.84 million as of May 27th, 2020. Mr. Mulligan owns 1,117,788 shares of Jazz Pharmaceuticals stock worth more than $134,838,766 as of March 28th. This net worth estimate does not reflect any other investments that Mr. Mulligan may own. Learn More about Seamus Mulligan's net worth.

How do I contact Seamus Mulligan?

The corporate mailing address for Mr. Mulligan and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at [email protected]. Learn More on Seamus Mulligan's contact information.

Has Seamus Mulligan been buying or selling shares of Jazz Pharmaceuticals?

Seamus Mulligan has not been actively trading shares of Jazz Pharmaceuticals during the last ninety days. Most recently, on Wednesday, May 27th, Seamus Mulligan bought 50,000 shares of Jazz Pharmaceuticals stock. The stock was acquired at an average cost of $117.31 per share, with a total value of $5,865,500.00. Following the completion of the transaction, the director now directly owns 1,117,788 shares of the company's stock, valued at $131,127,710.28. Learn More on Seamus Mulligan's trading history.

Who are Jazz Pharmaceuticals' active insiders?

Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Robert Iannone (EVP), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Jazz Pharmaceuticals?

During the last year, Jazz Pharmaceuticals insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $1,435,800.00. During the last year, insiders at the specialty pharmaceutical company sold shares 10 times. They sold a total of 13,870 shares worth more than $1,827,470.63. The most recent insider tranaction occured on March, 6th when CAO Patricia Carr sold 1,936 shares worth more than $231,623.04. Insiders at Jazz Pharmaceuticals own 4.4% of the company. Learn More about insider trades at Jazz Pharmaceuticals.

Information on this page was last updated on 3/6/2024.

Seamus Mulligan Insider Trading History at Jazz Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/27/2020Buy50,000$117.31$5,865,500.001,117,788View SEC Filing Icon  
11/15/2018Buy50,000$144.56$7,228,000.00View SEC Filing Icon  
8/25/2016Sell27,968$128.32$3,588,853.761,072,411View SEC Filing Icon  
2/23/2016Sell27,968$122.71$3,431,953.281,127,831View SEC Filing Icon  
11/23/2015Sell27,968$145.86$4,079,412.481,130,547View SEC Filing Icon  
3/25/2015Sell50,000$174.59$8,729,500.00View SEC Filing Icon  
12/26/2014Sell50,000$163.40$8,170,000.00View SEC Filing Icon  
9/25/2014Sell50,000$163.16$8,158,000.00View SEC Filing Icon  
9/24/2014Sell35,294$163.70$5,777,627.80View SEC Filing Icon  
9/11/2014Sell50,000$175.00$8,750,000.00View SEC Filing Icon  
6/25/2014Sell50,000$149.69$7,484,500.00View SEC Filing Icon  
3/4/2014Sell550,000$156.25$85,937,500.001,455,555View SEC Filing Icon  
See Full Table

Seamus Mulligan Buying and Selling Activity at Jazz Pharmaceuticals

This chart shows Seamus Mulligan's buying and selling at Jazz Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals logo
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $120.63
Low: $120.03
High: $121.07

50 Day Range

MA: $122.59
Low: $115.19
High: $132.77

2 Week Range

Now: $120.63
Low: $111.25
High: $147.98

Volume

80,267 shs

Average Volume

623,707 shs

Market Capitalization

$7.60 billion

P/E Ratio

19.71

Dividend Yield

N/A

Beta

0.59